
About Saroja Pharma Industries India Limited
Data last updated:
Saroja Pharma Industries India Limited is a public limited company based in Mumbai, Maharashtra, India, recognised as a startup by DPIIT. It operates in the chemical distribution and retail segment of the chemicals and materials sector. It was incorporated on 14 January 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24110MH2019PLC319508. Its GSTIN is 27ABBCS4207N1Z5 (Maharashtra). It is a listed company as per MCA records. Its shares are listed on NSE: SAROJA.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹4.02 Cr. It is led by directors including Biju Gopinathan Nair (Managing Director) and Manish Dasharath Kamble (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 305 Kailash Tower Shiv Shristi Complex Goregaon Link Road Mulund West, Mumbai, Maharashtra, India – 400080.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹70.13 Cr, a growth of 30.5% compared to the previous year. For the same year it recorded a net profit of ₹1.68 Cr (net margin 2.4%) and EBITDA of ₹3.73 Cr (EBITDA margin 5.3%). The net worth stands at ₹17.29 Cr (up 10.3% YoY). Total assets are valued at ₹31.7 Cr (up 26.1% YoY).
The company is associated with 1 brand: Saroja Pharma. As per MCA filings, the company has open charges of ₹9.48 Cr and satisfied charges of ₹6.55 Cr on record. The company has 3 deals on record (2 funding rounds, 1 ipo), with disclosed funding of ₹1.95 Cr; the latest was in September 2023. Its 5 peer companies in the Chemicals industry (Chemical Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 2 smaller; the largest is VPB Infratech Private Limited with revenue of ₹54.03 Cr.
Saroja Pharma Industries India Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0061715). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sarojapharma.com.
Company details
CIN history
Saroja Pharma Industries India has one previous CIN (Corporate Identification Number): U24110MH2019PTC319508. The current CIN is U24110MH2019PLC319508, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24110MH2019PLC319508 | Current |
| U24110MH2019PTC319508 | Previous |
Recognitions & Rankings of Saroja Pharma Industries India
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-19-0061715
Contact details
Saroja Pharma Industries India Limited's registered office is in Mumbai, Maharashtra. Its website is sarojapharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address305 Kailash Tower Shiv Shristi Complex Goregaon Link Road Mulund West, Mumbai, Maharashtra, India – 400080
- IndustryChemicals and Materials, Chemical Distribution & Retail
To see the full contact details of Saroja Pharma Industries India Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Saroja Pharma Industries India operates one associated brand: Saroja Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Specialty chemical trader, exporter, and supplier that offers a range of products, with a focus on pharmaceutical ingredients | sarojapharma.com |
Business activity
The main business activity of Saroja Pharma Industries India is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Saroja Pharma Industries India Limited, buy the company report.
Financials of Saroja Pharma Industries India Limited
FY 2025-26 filings availableSaroja Pharma Industries India Limited reported revenue of ₹70.13 Cr (up 30.5% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 70.13 | 53.73 | 40.67 | 50.19 | 55.63 | 36.66 |
| Revenue growth | +30.5% | +32.1% | -19.0% | -9.8% | +51.8% | - |
| EBITDA | 3.73 | 2.79 | 2.57 | 2.72 | 2.09 | 1.31 |
| EBITDA margin | +5.3% | +5.2% | +6.3% | +5.4% | +3.8% | +3.6% |
| Profit before tax | 2.24 | 1.46 | 1.22 | 1.49 | 1.56 | 1.05 |
| Net profit | 1.68 | 1.04 | 0.89 | 1.06 | 1.12 | 0.75 |
| Net profit margin | +2.4% | +1.9% | +2.2% | +2.1% | +2.0% | +2.1% |
| EPS (₹) | 4.02 | 2.57 | 2.18 | 3.61 | 50.49 | 731.30 |
| Balance sheet | ||||||
| Total assets | 31.70 | 25.13 | 20.38 | 15.28 | 10.16 | 3.95 |
| Net worth | 17.29 | 15.68 | 14.64 | 5.09 | 4.03 | 0.94 |
| Total debt | 14.41 | 9.46 | 5.73 | 10.18 | 6.14 | 3.02 |
| Cash & bank | 0.34 | 0.33 | 0.32 | 0.36 | 0.26 | 0.00 |
| Net working capital | 8.51 | 12.81 | 11.43 | 10.10 | 9.75 | 3.83 |
| Cash flow | ||||||
| Cash from operations | 7.44 | 1.15 | 1.02 | 2.19 | (3.67) | (1.05) |
| Cash from investing | (11.68) | (2.70) | (4.76) | (4.82) | (0.34) | (0.05) |
| Cash from financing | 4.25 | 1.56 | 3.70 | 2.73 | 4.27 | 1.03 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 70.13 | 53.73 | 40.67 | 50.19 | 55.63 | 36.66 |
| Revenue growth | +30.5% | +32.1% | -19.0% | -9.8% | +51.8% | - |
| Other income | 0.11 | 0.19 | 0.19 | 0.16 | 0.32 | 0.09 |
| Total expenses | 66.40 | 50.94 | 38.10 | 47.47 | 53.54 | 35.35 |
| Employee cost | 0.69 | 0.74 | 0.92 | 0.83 | 0.73 | 0.55 |
| EBITDA | 3.73 | 2.79 | 2.57 | 2.72 | 2.09 | 1.31 |
| EBITDA margin | +5.3% | +5.2% | +6.3% | +5.4% | +3.8% | +3.6% |
| Depreciation | 0.11 | 0.11 | 0.09 | 0.07 | 0.05 | 0.02 |
| Interest | 1.49 | 1.41 | 1.45 | 1.32 | 0.80 | 0.33 |
| Profit before tax | 2.24 | 1.46 | 1.22 | 1.49 | 1.56 | 1.05 |
| Tax | 0.62 | 0.42 | 0.33 | 0.43 | 0.44 | 0.30 |
| Net profit | 1.68 | 1.04 | 0.89 | 1.06 | 1.12 | 0.75 |
| Net profit margin | +2.4% | +1.9% | +2.2% | +2.1% | +2.0% | +2.1% |
| EPS (₹) | 4.02 | 2.57 | 2.18 | 3.61 | 50.49 | 731.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 4.02 | 4.02 | 4.02 | 2.94 | 0.23 | 0.01 |
| Reserves & surplus | 13.27 | 11.66 | 10.62 | 2.15 | 3.80 | 0.93 |
| Shareholders' funds (net worth) | 17.29 | 15.68 | 14.64 | 5.09 | 4.03 | 0.94 |
| Secured loans | 6.10 | 8.48 | 3.79 | 8.00 | 5.13 | 1.60 |
| Unsecured loans | 8.31 | 0.98 | 1.94 | 2.18 | 1.01 | 1.42 |
| Total debt | 14.41 | 9.46 | 5.73 | 10.18 | 6.14 | 3.02 |
| Total liabilities | 31.70 | 25.13 | 20.38 | 15.28 | 10.16 | 3.95 |
| Assets | ||||||
| Gross block | 2.90 | 2.84 | 2.74 | 2.36 | 0.42 | 0.12 |
| Net block | 2.18 | 2.50 | 2.51 | 2.22 | 0.35 | 0.09 |
| Capital work in progress | 20.34 | 8.61 | 6.13 | 1.79 | 0.00 | 0.00 |
| Investments | 0.54 | 0.34 | 0.20 | 0.14 | 0.04 | 0.00 |
| Inventories | 0.86 | 0.10 | 0.40 | 3.87 | 0.47 | 0.66 |
| Sundry debtors | 17.30 | 26.58 | 16.24 | 11.11 | 13.98 | 7.22 |
| Cash & bank balances | 0.34 | 0.33 | 0.32 | 0.36 | 0.26 | 0.00 |
| Loans & advances | 0.06 | 0.21 | 0.64 | 0.81 | 0.38 | 0.22 |
| Total current assets | 18.56 | 27.22 | 17.60 | 16.15 | 15.09 | 8.10 |
| Total current liabilities | 10.05 | 14.41 | 6.17 | 6.05 | 5.34 | 4.27 |
| Net working capital | 8.51 | 12.81 | 11.43 | 10.10 | 9.75 | 3.83 |
| Total assets | 31.70 | 25.13 | 20.38 | 15.28 | 10.16 | 3.95 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 0.33 | 0.32 | 0.36 | 0.26 | 0.00 | 0.08 |
| Net cash from operating activities | 7.44 | 1.15 | 1.02 | 2.19 | (3.67) | (1.05) |
| Net cash from investing activities | (11.68) | (2.70) | (4.76) | (4.82) | (0.34) | (0.05) |
| Net cash from financing activities | 4.25 | 1.56 | 3.70 | 2.73 | 4.27 | 1.03 |
| Net change in cash | 0.01 | 0.01 | (0.04) | 0.10 | 0.26 | (0.07) |
| Closing cash | 0.34 | 0.33 | 0.32 | 0.36 | 0.26 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +30.5% | +32.1% | -19.0% | -9.8% | +51.8% | - |
| EBITDA growth | +33.7% | +8.6% | -5.5% | +30.1% | +59.5% | - |
| PBT growth | +53.4% | +19.7% | -18.1% | -4.5% | +48.6% | +9997.0% |
| Net income growth | +61.5% | +16.9% | -16.0% | -5.4% | +49.3% | - |
| Revenue CAGR (3Y) | +11.8% | -1.2% | +3.5% | - | - | - |
| EBITDA CAGR (3Y) | +11.1% | +10.1% | +25.2% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +2.3% | +1.9% | +2.2% | +2.1% | +2.0% | +2.1% |
| Return on capital employed | +13.1% | +12.6% | +14.9% | +22.1% | +33.7% | +34.3% |
| Return on net worth | +9.8% | +6.8% | +8.9% | +23.3% | +45.9% | +77.7% |
| Debt / equity | 0.72 | 0.50 | 0.81 | 1.79 | 1.84 | 3.21 |
| Long-term debt / equity | 0.27 | 0.13 | 0.28 | 0.49 | 0.63 | 1.51 |
| Interest cover | 41.16 | 52.61 | 58.47 | 49.81 | 39.22 | 25.58 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 24.44 | 19.26 | 15.95 | 36.11 | 206.04 | 305.50 |
| Inventory turnover | 146.10 | 214.92 | 19.05 | 23.13 | 98.46 | 55.55 |
| Debtors turnover | 3.20 | 2.51 | 2.97 | 4.00 | 5.25 | 5.08 |
| EPS (₹) | 4.02 | 2.57 | 2.18 | 3.61 | 50.49 | 731.30 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 43.00 | 38.99 | 36.42 | 17.33 | 178.30 | 935.90 |
To see the full year-wise statements and ratios of Saroja Pharma Industries India Limited, buy the company report.
Board of directors of Saroja Pharma Industries India Limited
Saroja Pharma Industries India has 8 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anita Sethia | Director | 03 Sep 2025 | 1 Years 2 Months | Current |
| Pulinattu Nandakumar Also directs: Saroja Pharma Industries India Limited | Director | 02 Feb 2023 | 3 Years 9 Months | Current |
| Sonal Jain | Director | 09 May 2023 | 3 Years 6 Months | Current |
| Santosh Shivram Palav Also directs: Saroja Pharma Industries India Limited | Additional Director | 09 Oct 2025 | 1 Years 1 Months | Current |
| Biju Gopinathan Nair Also directs: Saroja Pharma Industries India Limited | Managing Director | 14 Jan 2019 | 7 Years 10 Months | Current |
| Manish Dasharath Kamble Also directs: Blue Deck Infraproject Private Limited | Whole-Time Director | 14 Jan 2019 | 7 Years 10 Months | Current |
Peer comparison
Saroja Pharma Industries India Limited is compared with the 5 companies closest to it by revenue in the Chemicals industry (Chemical Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Saroja Pharma Industries India Limitedthis company | ₹70.13 Cr (FY 2026) | ₹1.68 Cr | 2.4% | 30.5% | Mumbai, Maharashtra, India | |
| VPB Infratech Private Limited | ₹54.03 Cr (FY 2025) | 138.0% | Jaipur, Rajasthan, India | |||
| Jinendra Enterprise Private Limited | ₹54.02 Cr (FY 2025) | 36.0% | Ahmedabad, Gujarat, India | |||
| Rivercraft Uniglobal Enterprises Private Limited | ₹53.94 Cr (FY 2025) | -6.0% | Mumbai, Maharashtra, India | |||
| S.N. Dyechem Private Limited | ₹53.65 Cr (FY 2024) | 113.0% | New Delhi, Delhi, India | |||
| Roop Rasayan Industries Private Limited | ₹53.61 Cr (FY 2025) | -34.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Saroja Pharma Industries India Limited, buy the company report.
Auditor
Saroja Pharma Industries India Limited is audited by Pravin Chandak & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Pravin Chandak & Associates | FY 2023 | 116627W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 73.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 27.00%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 73.00% | 73.00% | 73.00% | 73.00% |
| Public | 27.00% | 27.00% | 27.00% | 27.00% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 21 Sep 2023 | 100793470 | Others | ₹28 Lakh | Open | |
| 14 Jun 2022 | 100582764 | Others | ₹8.5 Cr | Open | |
| 14 Jun 2022 | 100582766 | Others | ₹50 Lakh | Open | |
| 27 Jan 2022 | 100538166 | Others | ₹20 Lakh | Open | |
| 23 Jun 2020 | 100346613 | Others | ₹6.5 Cr | Satisfied |
To see the full charge records of Saroja Pharma Industries India Limited, buy the company report.
Total charge records: 6 View all charges
Deals & funding
Saroja Pharma Industries India Limited has 3 deals on record (2 funding rounds, 1 ipo), with disclosed funding of ₹1.95 Cr; the latest was in September 2023.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2023 | IPO | ₹9.11 Cr | Investors: Public Market Investors |
| Feb 2022 | Funding round | ₹1.75 Cr | Investors: an individual |
| Jun 2021 | Funding round | ₹20 Lakh | Investors: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Saroja Pharma Industries India Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Saroja Pharma Industries India Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Saroja Pharma Industries India has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27ABBCS4207N1Z5 | Maharashtra | Active | 21 Jan 2019 |
To see the full GST registrations and return filing status of Saroja Pharma Industries India Limited, buy the company report.
Recent activity
Saroja Pharma Industries India Limited has 16 board changes on record since 2019: 8 appointments and 8 cessations. The latest: Ravindra Shivaji Salaskar was appointed as Whole-Time Director on 09 Oct 2025.
17 earlier events are in the company report.
Frequently asked questions
Saroja Pharma Industries India is an active public limited company based in Mumbai, Maharashtra, India. The company works in chemical distribution and retail, within the chemicals and materials industry. It was incorporated on 14 January 2019 (7+ years old) and is registered under CIN U24110MH2019PLC319508. Listed on NSE: SAROJA.
Saroja Pharma Industries India reported revenue of ₹70.13 Cr for FY 2025-26 (up 30.5% YoY) based on standalone financials.
Saroja Pharma Industries India has 8 current directors:
- Biju Gopinathan Nair - Managing Director
- Manish Dasharath Kamble - Whole-Time Director
- Ravindra Shivaji Salaskar - Whole-Time Director
- Anita Sethia - Director
- Pulinattu Nandakumar - Director
- Sonal Jain - Director
- Santosh Shivram Palav - Additional Director
- Pinky Kataruka - Director
The latest financial statements of Saroja Pharma Industries India on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Saroja Pharma Industries India is 27ABBCS4207N1Z5, registered in Maharashtra.
The CIN (Corporate Identification Number) of Saroja Pharma Industries India is U24110MH2019PLC319508. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Saroja Pharma Industries India is a listed company as per MCA records. Its shares are listed on NSE (symbol: SAROJA).
Saroja Pharma Industries India was incorporated on 14 January 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.
Saroja Pharma Industries India has 3 deals on record (2 funding rounds, 1 ipo), with disclosed funding of ₹1.95 Cr; the latest was in September 2023.
The peers of Saroja Pharma Industries India by revenue are VPB Infratech Private Limited, Jinendra Enterprise Private Limited, Rivercraft Uniglobal Enterprises Private Limited, S.N. Dyechem Private Limited, Roop Rasayan Industries Private Limited, all in the Chemicals industry (Chemical Retail and Distribution), with the same principal business activity (wholesale trading).
Ravindra Shivaji Salaskar was appointed as Whole-Time Director on 09 Oct 2025. Santosh Shivram Palav was appointed as Additional Director on 09 Oct 2025. Anita Sethia ceased to be Additional Director on 29 Sep 2025. Saroja Pharma Industries India has 16 board changes on record in total.

